NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the first patient has been enrolled in the pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) for its lead product NOV-002 in combination with first-line chemotherapy. Thomas Lynch, M.D. and Panos Fidias, M.D. from Massachusetts General Hospital (MGH) are the trial co-Chairs. Dr. Lynch is Director of MGH’s Center for Thoracic Cancers and Dr. Fidias is Clinical Director for the Center.
